×
Photo: Description
Sinovac said on Monday (18) Monday that Coronavac’s effectiveness in his clinical trial in Brazil was almost 20 percentage points higher in a small group of participants who took the second dose after a longer period. Information from Reuters.
The protection rate of 1,394 participants who received a second dose of vaccine or placebo three weeks apart was almost 70%, according to a company spokesperson.
Most trial participants in Brazil received the second dose 14 days later.
Last week, Ricardo Palácios, Bhutantan’s director of medical clinical research, said at a press conference that the immune response could improve with longer intervals between the first and second doses.
Read more: Subscribe to the magazine Crusoé, who are not afraid to point out the true culprits of Brazilian ailments.
More news
:strip_icc()/i.s3.glbimg.com/v1/AUTH_bc8228b6673f488aa253bbcb03c80ec5/internal_photos/bs/2021/A/q/HNo2cbTDKQCWBFTbXgmg/fortnite-street-fighter-ryu-chunli.jpg?w=310&resize=310%2C&ssl=1)